| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.093 | 0.08 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.08 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.27 | 0.08 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.053 | 0.08 |